145 related articles for article (PubMed ID: 7684202)
1. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma.
Dobashi Y; Sakamoto A; Sugimura H; Mernyei M; Mori M; Oyama T; Machinami R
Am J Surg Pathol; 1993 Apr; 17(4):375-81. PubMed ID: 7684202
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid.
Soares P; Cameselle-Teijeiro J; Sobrinho-Simões M
Histopathology; 1994 Mar; 24(3):205-10. PubMed ID: 8200621
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma.
Shin MK; Kim JW
Asian Pac J Cancer Prev; 2014; 15(5):2341-4. PubMed ID: 24716981
[TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation in thyroid carcinoma.
Ho YS; Tseng SC; Chin TY; Hsieh LL; Lin JD
Cancer Lett; 1996 May; 103(1):57-63. PubMed ID: 8616809
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis.
Burstein DE; Nagi C; Wang BY; Unger P
Hum Pathol; 2004 Apr; 35(4):465-73. PubMed ID: 15116328
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical analysis of cyclin D1, p53, and p21waf1/cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland.
Goto A; Sakamoto A; Machinami R
Pathol Res Pract; 2001; 197(4):217-22. PubMed ID: 11358005
[TBL] [Abstract][Full Text] [Related]
8. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
[TBL] [Abstract][Full Text] [Related]
10. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
11. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
12. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.
Lam KY; Lo CY; Chan KW; Wan KY
Ann Surg; 2000 Mar; 231(3):329-38. PubMed ID: 10714625
[TBL] [Abstract][Full Text] [Related]
13. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
14. Mutations of p53 in thyroid carcinoma with an insular component.
Takeuchi Y; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Thyroid; 1999 Apr; 9(4):377-81. PubMed ID: 10319944
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
16. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
17. [Expression of protein p53: the marker of low neoplastic cell differentiation in thyroid carcinoma].
Szybiński P; Nowak W; Stachura J; Nowak K; Przybylik-Mazurek E; Buziak-Bereza M
Wiad Lek; 2001; 54 Suppl 1():88-94. PubMed ID: 12182067
[TBL] [Abstract][Full Text] [Related]
18. Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.
Patel MR; Bryson PC; Shores CG; Hart CF; Thorne LB; Deal AM; Zanation AM
Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):590-6. PubMed ID: 19528408
[TBL] [Abstract][Full Text] [Related]
19. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
20. cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis.
Sakr HI; Chute DJ; Nasr C; Sturgis CD
Diagn Pathol; 2017 Oct; 12(1):71. PubMed ID: 28974238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
